Pharmaceutical Industry Residency Program

Pharmaceutical Industry Residency Program (PIRP)

The Pharmaceutical Industry Residency Program, formerly named the Industrial Pharmacy Residency Program, is administered by the Leslie Dan Faculty of Pharmacy, University of Toronto, in cooperation with participating Pharmaceutical Companies as listed below. These one or two year specialty residencies develop critical knowledge and skills and provide experience within the stated functional area. This is a national educational residency program for graduates from a recognized Pharmacy degree program; it is not an application for a position with a pharmaceutical company.

Pharmaceutical Industry Residency Program (PIRP) Information Night

A virtual information session were held on Tuesday, May 7, 2024 from 6-8:30pm to provide an opportunity to learn more about the PIRP, the application process and meet with current residents and other pharmaceutical company representatives.

Certification

Over the last few years, many residents and company supervisors have communicated a desire to formally certify the program and we are excited to announce that we have successfully achieved program certification through the Leslie Dan Faculty of Pharmacy, University of Toronto.

Current residents are eligible for the certificate provided they complete the requirements outlined in the terms of reference.

The Leslie Dan Faculty of Pharmacy will continue to support PIRP’s ability to provide high, quality, experiential learning through:

• Skills and educational webinars and exposure to pharmaceutical industry experts
• Resume and interview skills workshops
• Opportunity to network with PIRP residents and pharmaceutical industry professionals
• Participation in a new mentoring program with a PIRP graduate
• Collaboration with and guidance from University of Toronto faculty liaisons
• Coordination to address issues and ensure program requirements are met

PIRP Fees 

To help fund this program, starting in the 2024-25 cycle the program fees are as follows: 
Pharmaceutical company fees based on the number of residency positions offered: 

Applicant and resident non-refundable fees: 

• $250 at application (Sept 2024) 
• $2250 once successfully matched with a company (Due May 2025) 
• $2500 payable three months after residency employment starts (Due August 2025) 

Applications Process - Opened on Tuesday, September 3, 2024 - Closed on Tuesday, October 1, 2024 at 5:00pm Eastern Time

Applications are now invited for Residencies 2025-2026. To apply:  

• If you are a current U of T student: Please click here where you will login with your UTORID to access the application form and process. 

• If you are not currently a U of T student, please click here for a login. (This may take 3-5 business days so please do as soon as possible). Once your account has been activated, you can login here. Please note that you will not receive an email confirmation once the account has been created and will have to manually check by logging in. 

In the interim, you may prepare to upload the following as part of the application: 

1. Applicant Contact Information 
2. University Transcripts from Pharmacy program (in PDF format; unofficial copy accepted – verification may be required) 
3. Resume or CV 
4. Reference form (listing contact information of two referees) (click here) 

Note: Applications will be accepted until Tuesday, October 1st, 2024 at 5:00pm ET. Approved applicants will then have until Monday, October 21st, 2024 at 5:00pm ET to finalize their selection of positions. We recommend initiating your application through the CLN “here” link above as soon as possible. 

Residency matching results from individual companies will be communicated to successful applicants starting on February 28, 2025 – March 14, 2025, and no longer align with the Hospital Residency Program timelines. 

If you have any questions about the application process, please contact: pharm.residency@utoronto.ca. 

Key Dates for 2025-26 Residency Application Cycle

The Product Development Regulatory and Annual Product Quality Review residencies with Roche, and the residencies with AstraZeneca will be 24 months in length. Please review the updated Terms of Reference document for more information.

2025-2026 Residency Program Participating Companies & Specialties 

1. Abbvie: Market Access, Immunology and Oncology 
2. Amgen: Medical Information and Medical Affairs | Value, Market Access & Policy
3. Alexion AstraZeneca: Global Medical Information and Medical Review - Neurology
4. AstraZeneca: Global Clinical Development, Oncology | Global Regulatory Affairs, Oncology | Market Access 
5. Bayer: Medical Affairs, Oncology  
6. Boehringer Ingelheim: Medical Affairs, Oncology and Mental Health | Medical Affairs, Inflammation  
7. Eisai: Medical Affairs, Oncology and Neurology 
8. Gilead: Medical Affairs, HIV
9. Lilly: Medical Affairs, Operations and Capabilities | Medical Affairs, Medical Information | Medical Affairs, Oncology | Medical Affairs, Immunology | Market Access, Pricing and Reimbursement 
10. Novo Nordisk: Medical Affairs and Medical Operations 
11. Pfizer: Medical Affairs Primary Care and Oncology 
12. Roche: Medical Affairs, Strategy   
13. Sanofi: Medical Affairs, Oncology | Medical Affairs, Rare Diseases | Medical Affairs, Immunology | Medical Affairs, Dermatology | Medical Affairs, Respirology | Medical Affairs, Gastrointestinal and Nasal Polyps | Medical Affairs Operations, Specialty Care | Medical Affairs, Vaccines | Medical Affairs, General Medicine | Market Access, Dupixent | Market Access, Oncology and Rare Diseases 

Download the PIRP Table of Positions 2025-26 below for more information